|
1
|
Bradford PT, Devesa SS, Anderson WF and
Toro JR: Cutaneous lymphoma incidence patterns in the United
States: a population-based study of 3884 cases. Blood.
113:5064–5073. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Criscione VD and Weinstock MA: Incidence
of cutaneous T-cell lymphoma in the United States, 1973–2002. Arch
Dermatol. 143:854–859. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pham-Ledard A, Prochazkova-Carlotti M,
Laharanne E, Vergier B, Jouary T, Beylot-Barry M and Merlio JP:
IRF4 gene rearrangements define a subgroup of CD30-positive
cutaneous T-cell lymphoma: a study of 54 cases. J Invest Dermatol.
130:816–825. 2010. View Article : Google Scholar
|
|
4
|
Zackheim HS: Cutaneous T cell lymphoma:
update of treatment. Dermatology. 199:102–105. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marszałek A, Grzanka A, Grzanka D and
Placek W: Correct answer to the quiz. Check your diagnosis Mycosis
fungoides - case report and short overview of the literature. Pol J
Pathol. 61:54–61. 2010.
|
|
6
|
Al Hothali GI: Review of the treatment of
mycosis fungoides and Sézary syndrome: a stage-based approach. Int
J Health Sci. 7:220–239. 2013.
|
|
7
|
Wang Y, Su M, Zhou LL, Tu P, Zhang X,
Jiang X and Zhou Y: Deficiency of SATB1 expression in Sezary cells
causes apoptosis resistance by regulating FasL/CD95L transcription.
Blood. 117:3826–3835. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zackheim HS: Treatment of mycosis
fungoides/Sezary syndrome: the University of California, San
Francisco (UCSF) approach. Int J Dermatol. 42:53–56. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Costantini P, Jacotot E, Decaudin D and
Kroemer G: Mitochondrion as a novel target of anticancer
chemotherapy. J Natl Cancer Inst. 92:1042–1053. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Trautinger F, Knobler R, Willemze R, et
al: EORTC consensus recommendations for the treatment of mycosis
fungoides/Sézary syndrome. Eur J Cancer. 42:1014–1030. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Grzanka A, Grzanka D, Gagat M, Tadrowski
T, Sokołowska-Wojdyło M, Marszałek A and Placek W: Correlation of
SATB1 expression with clinical course of cutaneous T-cell
lymphomas. Pol J Pathol. 63:101–105. 2012.PubMed/NCBI
|
|
12
|
Dickinson LA, Joh T, Kohwi Y and
Kohwi-Shigematsu T: A tissue-specific MAR/SAR DNA-binding protein
with unusual binding site recognition. Cell. 70:631–645. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Galande S, Purbey PK, Notani D and Kumar
PP: The third dimension of gene regulation: organization of dynamic
chromatin loopscape by SATB1. Curr Opin Genet Dev. 17:408–414.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Purbey PK, Singh S, Notani D, Kumar PP,
Limaye AS and Galande S: Acetylation-dependent interaction of SATB1
and CtBP1 mediates transcriptional repression by SATB1. Mol Cell
Biol. 29:1321–1337. 2009. View Article : Google Scholar :
|
|
15
|
Liu J, Barnett A, Neufeld EJ and Dudley
JP: Homeoproteins CDP and SATB1 interact: potential for
tissue-specific regulation. Mol Cell Biol. 19:4918–4926.
1999.PubMed/NCBI
|
|
16
|
Alvarez JD, Yasui DH, Niida H, Joh T, Loh
DY and Kohwi-Shigematsu T: The MAR-binding protein SATB1
orchestrates temporal and spatial expression of multiple genes
during T-cell development. Genes Dev. 14:521–535. 2000.PubMed/NCBI
|
|
17
|
Meng W-J, Yan H, Zhou B, et al:
Correlation of SATB1 overexpression with the progression of human
rectal cancer. Int J Colorectal Dis. 27:143–150. 2012. View Article : Google Scholar
|
|
18
|
Han B, Luan L, Xu Z and Wu B: Expression
and biological roles of SATB1 in human bladder cancer. Tumour Biol.
34:2943–2949. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mao L, Yang C, Wang J, Li W, Wen R, Chen J
and Zheng J: SATB1 is overexpressed in metastatic prostate cancer
and promotes prostate cancer cell growth and invasion. J Transl
Med. 11:1112013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shen Z, Zeng Y, Guo J, et al:
Over-expression of the special AT rich sequence binding protein 1
(SATB1) promotes the progression of nasopharyngeal carcinoma:
association with EBV LMP-1 expression. J Transl Med. 11:2172013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ordinario E, Han H-J, Furuta S, et al: ATM
suppresses SATB1-induced malignant progression in breast epithelial
cells. PloS One. 7:e517862012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Q, Qian J, Wang F and Ma Z: Cellular
prion protein accelerates colorectal cancer metastasis via the
Fyn-SP1-SATB1 axis. Oncol Rep. 28:2029–2034. 2012.PubMed/NCBI
|
|
23
|
Fang XF, Hou ZB, Dai XZ, et al: Special
AT-rich sequence-binding protein 1 promotes cell growth and
metastasis in colorectal cancer. World J Gastroenterol.
19:2331–2339. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kobierzycki C, Wojnar A and Dziegiel P:
Expression of SATB1 protein in the ductal breast carcinoma tissue
microarrays - preliminary study. Folia Histochem Cytobiol.
51:333–338. 2013. View Article : Google Scholar
|
|
25
|
Grzanka D, Gagat M and Izdebska M:
Involvement of the SATB1/F-actin complex in chromatin
reorganization during active cell death. Int J Mol Med.
33:1441–1450. 2014.PubMed/NCBI
|
|
26
|
Edelson RL: Cutaneous T cell lymphoma:
mycosis fungoides, Sézary syndrome, and other variants. J Am Acad
Dermatol. 2:89–106. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Abel EA: Clinical features of cutaneous
T-cell lymphoma. Dermatol Clin. 3:647–664. 1985.PubMed/NCBI
|
|
28
|
Willemze R, Kerl H, Sterry W, et al: EORTC
classification for primary cutaneous lymphomas: a proposal from the
Cutaneous Lymphoma Study Group of the European Organization for
Research and Treatment of Cancer. Blood. 90:354–371.
1997.PubMed/NCBI
|
|
29
|
Willemze R, Jaffe ES, Burg G, et al:
WHO-EORTC classification for cutaneous lymphomas. Blood.
105:3768–3785. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sausville EA, Eddy JL, Makuch RW, et al:
Histopathologic staging at initial diagnosis of mycosis fungoides
and the Sézary syndrome. Definition of three distinctive prognostic
groups. Ann Intern Med. 109:372–382. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim YH, Chow S, Varghese A and Hoppe RT:
Clinical characteristics and long-term outcome of patients with
generalized patch and/or plaque (T2) mycosis fungoides. Arch
Dermatol. 135:26–32. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Weinstock MA and Reynes JF: The changing
survival of patients with mycosis fungoides: a population-based
assessment of trends in the United States. Cancer. 85:208–212.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
van Doorn R, van Haselen CW, van Voorst
Vader PC, et al: Mycosis fungoides: disease evolution and prognosis
of 309 Dutch patients. Arch Dermatol. 136:504–510. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim YH, Liu HL, Mraz-Gernhard S, Varghese
A and Hoppe RT: Long-term outcome of 525 patients with mycosis
fungoides and Sezary syndrome: clinical prognostic factors and risk
for disease progression. Arch Dermatol. 139:857–866. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Agar NS, Wedgeworth E, Crichton S, et al:
Survival outcomes and prognostic factors in mycosis
fungoides/Sézary syndrome: validation of the revised International
Society for Cutaneous Lymphomas/European Organisation for Research
and Treatment of Cancer staging proposal. J Clin Oncol.
28:4730–4739. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hess Schmid M, Dummer R, Kempf W, Hilty N
and Burg G: Mycosis fungoides with mucinosis follicularis in
childhood. Dermatology. 198:284–287. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Talpur R, Singh L, Daulat S, et al:
Long-term outcomes of 1,263 patients with mycosis fungoides and
Sézary syndrome from 1982 to 2009. Clin Cancer Res. 18:5051–5060.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vicente A, Martí RM, Martín E, Estrach T,
Herrero C and Mascaró JM: Mycosis fungoides with oral involvement.
Int J Dermatol. 30:864–866. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Vonderheid EC, Diamond LW, van Vloten WA,
et al: Lymph node classification systems in cutaneous T-cell
lymphoma. Evidence for the utility of the Working Formulation of
Non-Hodgkin’s Lymphomas for Clinical Usage. Cancer. 73:207–218.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bernengo MG, Quaglino P, Novelli M, et al:
Prognostic factors in Sézary syndrome: a multivariate analysis of
clinical, haematological and immunological features. Ann Oncol.
9:857–863. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Diamandidou E, Colome M, Fayad L, Duvic M
and Kurzrock R: Prognostic factor analysis in mycosis
fungoides/Sézary syndrome. J Am Acad Dermatol. 40:914–924. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fraser-Andrews EA, Woolford AJ,
Russell-Jones R, Seed PT and Whittaker SJ: Detection of a
peripheral blood T cell clone is an independent prognostic marker
in mycosis fungoides. J Invest Dermatol. 114:117–121. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wasik MA, Vonderheid EC, Bigler RD, Marti
R, Lessin SR, Polansky M and Kadin ME: Increased serum
concentration of the soluble interleukin-2 receptor in cutaneous
T-cell lymphoma. Clinical and prognostic implications. Arch
Dermatol. 132:42–47. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Diamandidou E, Colome-Grimmer M, Fayad L,
Duvic M and Kurzrock R: Transformation of mycosis fungoides/Sezary
syndrome: clinical characteristics and prognosis. Blood.
92:1150–1159. 1998.PubMed/NCBI
|
|
45
|
Vergier B, de Muret A, Beylot-Barry M, et
al: Transformation of mycosis fungoides: clinicopathological and
prognostic features of 45 cases. French Study Group of Cutaneous
Lymphomas. Blood. 95:2212–2218. 2000.PubMed/NCBI
|
|
46
|
Vidulich KA, Talpur R, Bassett RL and
Duvic M: Overall survival in erythrodermic cutaneous T-cell
lymphoma: an analysis of prognostic factors in a cohort of patients
with erythrodermic cutaneous T-cell lymphoma. Int J Dermatol.
48:243–252. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Olsen E, Vonderheid E, Pimpinelli N, et
al: Revisions to the staging and classification of mycosis
fungoides and Sezary syndrome: a proposal of the International
Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma
task force of the European Organization of Research and Treatment
of Cancer (EORTC). Blood. 110:1713–1722. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Scarisbrick JJ, Kim YH, Whittaker SJ, Wood
GS, Vermeer MH, Prince HM and Quaglino P: Prognostic factors,
prognostic indices and staging in mycosis fungoides and Sézary
syndrome: where are we now? Br J Dermatol. 170:1226–1236. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Martí RM, Estrach T, Reverter JC and
Mascaró JM: Prognostic clinicopathologic factors in cutaneous
T-cell lymphoma. Arch Dermatol. 127:1511–1516. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Han HJ, Russo J, Kohwi Y and
Kohwi-Shigematsu T: SATB1 reprogrammes gene expression to promote
breast tumour growth and metastasis. Nature. 452:187–193. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Pavan Kumar P, Purbey PK, Sinha CK, Notani
D, Limaye A, Jayani RS and Galande S: Phosphorylation of SATB1, a
global gene regulator, acts as a molecular switch regulating its
transcriptional activity in vivo. Mol Cell. 22:231–243. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Yasui D, Miyano M, Cai S, Varga-Weisz P
and Kohwi-Shigematsu T: SATB1 targets chromatin remodelling to
regulate genes over long distances. Nature. 419:641–645. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Cai S, Han HJ and Kohwi-Shigematsu T:
Tissue-specific nuclear architecture and gene expression regulated
by SATB1. Nat Genet. 34:42–51. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
54
|
Notani D, Limaye AS, Kumar PP and Galande
S: Phosphorylation-dependent regulation of SATB1, the higher-order
chromatin organizer and global gene regulator. Methods Mol Biol.
647:317–335. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Satoh Y, Yokota T, Sudo T, et al: The
Satb1 protein directs hematopoietic stem cell differentiation
toward lymphoid lineages. Immunity. 38:1105–1115. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Will B, Vogler TO, Bartholdy B, et al:
Satb1 regulates the self-renewal of hematopoietic stem cells by
promoting quiescence and repressing differentiation commitment. Nat
Immunol. 14:437–445. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Agrelo R, Souabni A, Novatchkova M, et al:
SATB1 defines the developmental context for gene silencing by Xist
in lymphoma and embryonic cells. Dev Cell. 16:507–516. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zhou LY, Liu F, Tong J, Chen QQ and Zhang
FW: Expression of special AT-rich sequence-binding protein mRNA and
its clinicopathological significance in non-small cell lung cancer.
Nan Fang Yi Ke Da Xue Xue Bao. 29:534–537. 2009.(In Chinese).
PubMed/NCBI
|
|
59
|
Li QQ, Chen ZQ, Xu JD, Cao X-X, Chen Q,
Liu XP and Xu ZD: Overexpression and involvement of special AT-rich
sequence binding protein 1 in multidrug resistance in human breast
carcinoma cells. Cancer Sci. 101:80–86. 2010. View Article : Google Scholar
|
|
60
|
Lu X, Cheng C, Zhu S, et al: SATB1 is an
independent prognostic marker for gastric cancer in a Chinese
population. Oncol Rep. 24:981–987. 2010.PubMed/NCBI
|
|
61
|
Zhao XD, Ji W, Zhang W, He LX, Yang J,
Liang HJ and Wang LL: Overexpression of SATB1 in laryngeal squamous
cell carcinoma. ORL J Otorhinolaryngol Relat Spec. 72:1–5. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Chen H, Takahara M, Oba J, et al:
Clinicopathologic and prognostic significance of SATB1 in cutaneous
malignant melanoma. J Dermatol Sci. 64:39–44. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Zhang L, Cheng F, He R, Chen H, Liu Y and
Sun J: Inhibition of SATB1 by shRNA suppresses the proliferation of
cutaneous malignant melanoma. Cancer Biother Radiopharm. 29:77–82.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Bayer AL, Chirinos J, Cabello C, Yang J,
Matsutani T, Malek TR and Levy RB: Expansion of a restricted
residual host T reg-cell repertoire is dependent on IL-2 following
experimental auto-logous hematopoietic stem transplantation. Eur J
Immunol. 41:3467–3478. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Berger CL, Tigelaar R, Cohen J, Mariwalla
K, Trinh J, Wang N and Edelson RL: Cutaneous T-cell lymphoma:
malignant proliferation of T-regulatory cells. Blood.
105:1640–1647. 2005. View Article : Google Scholar
|
|
66
|
Capriotti E, Vonderheid EC, Thoburn CJ,
Wasik MA, Bahler DW and Hess AD: Expression of T-plastin, FoxP3 and
other tumor-associated markers by leukemic T-cells of cutaneous
T-cell lymphoma. Leuk Lymphoma. 49:1190–1201. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Heid JB, Schmidt A, Oberle N, Goerdt S,
Krammer PH, Suri-Payer E and Klemke CD:
FOXP3+CD25− tumor cells with regulatory
function in Sézary syndrome. J Invest Dermatol. 129:2875–2885.
2009. View Article : Google Scholar : PubMed/NCBI
|
